Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Globe Newswire

15:30 EDT 21st September 2018 | BioPortfolio

Here are the most relevant search results for "Globe Newswire" found in our extensive news archives from over 250 global news sources.

More Information about Globe Newswire on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Globe Newswire for you to read. Along with our medical data and news we also list Globe Newswire Clinical Trials, which are updated daily. BioPortfolio also has a large database of Globe Newswire Companies for you to search.

Showing News Articles 1–25 of 21,000+ from Globe Newswire

Thursday 20th September 2018

Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering

HOUSTON, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path),  a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into definitive agreements with several healthcare focused institutional investors for the issuance...

XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte

EMERYVILLE, Calif., Sept. 21, 2018 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today that for $15.0 million, it has acquired from Agenus (NASDAQ: AGEN) a partial interest position in the rights to potential milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte under their collaborations with Agenus.    ...

Arcturus Therapeutics Expands Management Team

Arcturus Appoints Senior VP of Business Development & Alliance Management and VP of Translational Biology SAN DIEGO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced the appointment of Kevin T. Skol as Senior Vice President of Business Development & Alliance Management, and Suezanne Parker, Ph.D., as Vice Pr...

Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union

Apealea receives positive CHMP opinion in the European Union for treatment of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer in combination with carboplatin in first relapse Uppsala, Sweden, September 21, 2018 – Oasmia Pharmaceutical AB (NASDAQ: OASM) today announce that the Committee for Medicinal Products for Human Use (CHMP) of the Eur...

VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation’s CF Climb

-Fundraising event at AT&T Stadium on September 22 supports the Dallas-Fort Worth chapter of the Cystic Fibrosis Foundation- CAMPBELL, Calif., Sept. 21, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that it is supporting the Dallas-Fort Worth chapter of the Cystic Fibrosis Foundation (CFF) in its CF Climb fundraising e...

Aleafia Added to Leading Cannabis ETF After Surge in Business Performance

Horizons Marijuana Life Sciences ETF has $1.1B Invested in Cannabis Sector TORONTO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), one of Canada’s leading, vertically integrated cannabis companies, is announcing that it has been added to the Horizons Marijuana Life Sciences ETF (HMMJ:TSX).  HMMJ is the ...

September 21st: World Alzheimer’s Day around the world

Working together to raise awareness and challenge the stigmaWith a concerted effort, science will prevail Oryzon has two ongoing clinical trials in AD with Vafidemstat MADRID, Spain and CAMBRIDGE, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics, its scientists and staff want today to join the international chorus of voices to raise awareness of this disease that affects millions of p...

Scythian Biosciences Closes Acquisition of MMJ International Investments Inc.

Closing of Argentine Acquisition is Key Benchmark in Finalization of Previously Announced $193 Million Sale of Assets in Latin America, Which as of Prior Day Close was Valued At Approximately $313 Million Scythian Appoints Andy DeFrancesco as Chairman TORONTO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (Frankfurt: 9SB) (OTC – ...

Vilacto Bio Unveils Development Programs for LACTOACTIVE iTHER®  

COPENHAGEN, Denmark, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Vilacto Bio Inc. (OTC QB:VIBI) has revealed the initial five areas of development for its new LACTOACTIVE iTHER® compound. LACTOACTIVE iTHER® is a new LACTOACTIVE variant that combines potent immune-system enhancement with a proven nanoparticle drug delivery system. “Our own research suggests, and we firmly believe, that LACTOACTIVE...

Vericel to Present at Multiple Upcoming Conferences

CAMBRIDGE, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, will be presenting at the following investor and industry conferences: Nick Colangelo, president and CEO, will present at the Ladenburg 2018 Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at 11:30 A...

Yield10 Bioscience Grants Research License to Forage Genetics to Evaluate Novel Yield Traits in Sorghum

WOBURN, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today announced that it has granted a non-exclusive research license to Forage Genetics International, LLC, a subsidiary of Land O’Lakes, Inc., to evaluate five novel yield traits in ...

Top-Rated Las Vegas PLANET 13/MEDIZIN Dispensary Reports Record Growth Prior to Planet 13 Superstore Opening -- CFN Media

SEATTLE, Sept. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Planet 13 Holdings Inc.'s (CSE:PLTH) (OTCQB:PLNHF) new state-of-the-art cannabis superstore opening in Las Vegas. Planet 13 Holdings Inc. (CSE:PLTH) (...

Predictive Technology Group to Present at Two Upcoming Investment Conferences

SALT LAKE CITY, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a life-sciences technology company, announces that Bradley Robinson, President and CEO, will present a corporate update at two upcoming investment conferences: LD Micro New York Conference on Tuesday, September 25, at 2:00 p.m. Eastern time in New York City; andThe MicroCap Conference on Mon...

Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease

Preliminary Results Indicate Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal®) to pegunigalsidase alfa (PRX-102) A deterioration trend in patients’ kidney function on agalsidase alfa (Replagal®) was reversed to an improvement trend when switched to pegunigalsidase alfa (PRX-102)  Presentation with full Data to be held at the1st Canadian Symposium on ...

JSC Olainfarm Group sales increase by 13% in August

Consolidated Results of 8 months and August, 2018 Preliminary consolidated Olainfarm Group sales results in August of 2018 have reached 9.1million euros and that is 13% more compared to corresponding period of 2017. Largest sales growth   was reached in   Italy and Kirgizstan where due to the low base in 2017, sales have increased by 11650% and 292% respectively. Sales declined at most in...

ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting

SINGAPORE, Sept. 21, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, announced today the presentation of two posters on varlitinib at the 21st Annual Meeting of Chinese Society of Clinical Oncology (CSCO) held in Xia...

Shire Receives Approval of FIRAZYR® (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan

Shire Receives Approval of FIRAZYR® (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan -       FIRAZYR is the first subcutaneous on-demand therapy for HAE in Japan, allowing patients to treat symptoms of acute HAE attacks-       Approval supported by data from dedicated study of HAE patients in Japan -       HAE is a rare, genetic disorde...

BeiGene Presents Results on Anti-PD-1 Antibody Tislelizumab in Chinese Patients with Lung Cancers at the Annual Meeting of the Chinese Society of Clinical Oncology

BEIJING, China, and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, presented clinical data on tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with lu...

Molecular Templates, Inc. Announces Pricing of Public Offering of Common Stock

AUSTIN, Texas, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced the pricing of its underwritten public offering of 8,200,000 shares of its com...

Wednesday 19th September 2018

Supernus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

ROCKVILLE, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and Company update as well as host investor meetings, at the 2018 Cantor Fitzgerald Globa...

aTyr Pharma to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

SAN DIEGO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla, M.D., M.S., president and chief executive officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York City on Tuesday,...

Rubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, announced today that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Tuesday, Octo...

Opiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose

SANTA MONICA, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it has entered into a multi-year contract with potential funding up to a maximum of approximately $4.6 million, with the Biomedical Advanced Research and Development Au...

Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections

– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MD

UPDATE— Taconic Biosciences Becomes the First Animal Model Provider on General Services Administration Contract Schedule

RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS). GSS is a leading dedicated distributor of laboratory equipment to federal, state, and local governments on contract with the GSA (General Services Administration).  By having...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks